Integra Lifesciences Holdings (IART) Receivables (2009 - 2026)

Integra Lifesciences Holdings' Receivables history runs 18 years deep, the most recent figure standing at $271.1 million for Q1 2026.

• In Q1 2026, Receivables rose 5.24% year-over-year to $271.1 million; the TTM figure through Mar 2026 stood at $271.1 million (up 5.24% YoY), while the FY2025 annual figure was $285.7 million, up 2.58% from the prior year.
• Receivables came in at $271.1 million for Q1 2026 at Integra Lifesciences Holdings, down from $285.7 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $288.0 million in Q2 2025 to a low of $246.2 million in Q1 2022.
• A 5-year average of $265.9 million and a median of $267.1 million in 2025 frame the typical range for Receivables.
• Across the five-year window, Receivables grew 12.47% in 2022 and retreated 5.87% in 2024, its largest moves.
• Integra Lifesciences Holdings' Receivables stood at $273.6 million in 2022, then declined by 1.84% to $268.6 million in 2023, then climbed by 3.71% to $278.5 million in 2024, then grew by 2.58% to $285.7 million in 2025, then retreated by 5.12% to $271.1 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $271.1 million, $285.7 million, and $267.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison